Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could significantly enhance the development of MS therapies, including its investigational candidate Lucid-MS.
Preliminary imaging data from the study have shown encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, which are often difficult to detect with conventional imaging techniques. This advancement could provide a more precise method for monitoring disease progression and treatment response in MS patients. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the FDA in March 2026.
Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models, targeting the underlying mechanism of multiple sclerosis. The imaging study’s progress is a critical step toward validating a biomarker that could accelerate the clinical development of Lucid-MS and other demyelination therapies.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is advancing Lucid-MS. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets the over-the-counter product UNBUZZD, and receives royalty payments from Unbuzzd sales.
For more information, the full press release is available at https://ibn.fm/4IZ0y. Updates on QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
